Lilly discontinues certain insulin products
Executive Summary
Lilly will discontinue select insulin formulations by year-end due to declining demand, the company says July 6. Lilly will halt sales of Humulin Ultralente and Lente human insulins and Iletin II and NPH pork insulins. "Less than 2% of the patients with diabetes who use insulin in the U.S. will be impacted," Lilly said. Remaining on the market are the R, N, 70/30 and 50/50 formulations of Humulin, as well as the Humalog (insulin lispro injection) family of products...
|
Lilly will discontinue select insulin formulations by year-end due to declining demand, the company says July 6. Lilly will halt sales of Humulin Ultralente and Lente human insulins and Iletin II and NPH pork insulins. "Less than 2% of the patients with diabetes who use insulin in the U.S. will be impacted," Lilly said. Remaining on the market are the R, N, 70/30 and 50/50 formulations of Humulin, as well as the Humalog (insulin lispro injection) family of products.... |